Relmada Therapeutics ( (RLMD) ) has shared an update.

Relmada Therapeutics Inc (RLMD) stock saw a decline, ending the day at $0.45 which represents a decrease of $-0.07 or -13.46% from the prior close of $0.52. The stock opened at $0.52 and touched a low ...

Dec 9 (Reuters) - Relmada Therapeutics (RLMD.O), opens new tab said on Monday it would discontinue the two late-stage studies planned for the development of its depression drug and explore ...

Relmada Therapeutics has put itself up for sale following the failure of the biotechnology company's lead asset in a late-stage study. Relmada on Monday said it is ending Phase 3 studies of its ...

Mizuho has recently reduced Relmada Therapeutics Inc (RLMD) stock to Neutral rating, as announced on December 5, 2024, according to Finviz. Earlier, on September 17, 2024, Jefferies had raised the ...

Relmada Therapeutics , Inc. (NASDAQ:RLMD), a pharmaceutical company currently valued at $13.5 million, announced the appointment of Paul Kelly as Chief Operating Officer (COO) effective January 1 ...

CORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company ...

Fintel reports that on December 4, 2024, Leerink Partners downgraded their outlook for Relmada Therapeutics (NasdaqGS:RLMD) from Outperform to Market Perform. Analyst Price Forecast Suggests 1,842 ...

Relmada Therapeutics said an interim analysis of a study assessing a treatment for major depressive disorder is futile and unlikely to meet the primary efficacy endpoint with statistical significance.

NASDAQ:RLMD opened at $0.46 on Thursday. The stock’s 50 day moving average price is $3.12 and its two-hundred day moving average price is $3.15. Relmada Therapeutics has a 12-month low of $0.43 ...

Relmada Therapeutics , Inc. (NASDAQ:RLMD), a pharmaceutical company currently valued at $13.5 million, announced the appointment of Paul Kelly as Chief Operating Officer (COO) effective January 1, ...